CSL Ltd - Asset Resilience Ratio
CSL Ltd (CSL) has an Asset Resilience Ratio of 0.41% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CSL net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2023)
This chart shows how CSL Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CSL asset base.
Liquid Assets Composition Over Time
This chart breaks down CSL Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CSL strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$157.48 Million | 0.41% |
| Total Liquid Assets | AU$157.48 Million | 0.41% |
Asset Resilience Insights
- Limited Liquidity: CSL Ltd maintains only 0.41% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSL Ltd Industry Peers by Asset Resilience Ratio
Compare CSL Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for CSL Ltd (1997–2023)
The table below shows the annual Asset Resilience Ratio data for CSL Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.02% | AU$9.00 Million ≈ $6.37 Million |
AU$54.43 Billion ≈ $38.52 Billion |
+0.01pp |
| 2022-06-30 | 0.01% | AU$4.20 Million ≈ $2.97 Million |
AU$41.22 Billion ≈ $29.17 Billion |
-0.01pp |
| 2021-06-30 | 0.02% | AU$3.60 Million ≈ $2.55 Million |
AU$18.16 Billion ≈ $12.85 Billion |
0.00pp |
| 2020-06-30 | 0.02% | AU$3.30 Million ≈ $2.33 Million |
AU$15.46 Billion ≈ $10.94 Billion |
+0.02pp |
| 2019-06-30 | 0.00% | AU$279.62K ≈ $197.85K |
AU$12.27 Billion ≈ $8.68 Billion |
-0.01pp |
| 2018-06-30 | 0.01% | AU$1.18 Million ≈ $833.32K |
AU$10.73 Billion ≈ $7.60 Billion |
-0.05pp |
| 2017-06-30 | 0.06% | AU$5.20 Million ≈ $3.68 Million |
AU$9.12 Billion ≈ $6.45 Billion |
+0.05pp |
| 2016-06-30 | 0.01% | AU$601.19K ≈ $425.38K |
AU$7.58 Billion ≈ $5.36 Billion |
-0.03pp |
| 2015-06-30 | 0.04% | AU$1.98 Million ≈ $1.40 Million |
AU$4.87 Billion ≈ $3.44 Billion |
+0.04pp |
| 2014-06-30 | 0.00% | AU$300.00K ≈ $212.27K |
AU$6.28 Billion ≈ $4.44 Billion |
0.00pp |
| 2013-06-30 | 0.01% | AU$500.00K ≈ $353.78K |
AU$5.98 Billion ≈ $4.23 Billion |
-0.02pp |
| 2012-06-30 | 0.03% | AU$1.86 Million ≈ $1.32 Million |
AU$6.03 Billion ≈ $4.26 Billion |
-0.32pp |
| 2011-06-30 | 0.36% | AU$20.57 Million ≈ $14.55 Million |
AU$5.79 Billion ≈ $4.10 Billion |
+0.35pp |
| 2010-06-30 | 0.01% | AU$343.08K ≈ $242.75K |
AU$4.09 Billion ≈ $2.89 Billion |
0.00pp |
| 2009-06-30 | 0.01% | AU$550.99K ≈ $389.86K |
AU$4.75 Billion ≈ $3.36 Billion |
-0.02pp |
| 2008-06-30 | 0.03% | AU$1.45 Million ≈ $1.02 Million |
AU$4.49 Billion ≈ $3.18 Billion |
+0.02pp |
| 2007-06-30 | 0.01% | AU$426.98K ≈ $302.12K |
AU$3.02 Billion ≈ $2.14 Billion |
-0.17pp |
| 2006-06-30 | 0.19% | AU$4.31 Million ≈ $3.05 Million |
AU$2.29 Billion ≈ $1.62 Billion |
-4.46pp |
| 2002-06-30 | 4.64% | AU$60.45 Million ≈ $42.77 Million |
AU$1.30 Billion ≈ $921.05 Million |
-8.45pp |
| 2001-06-30 | 13.10% | AU$60.87 Million ≈ $43.07 Million |
AU$464.77 Million ≈ $328.86 Million |
-30.45pp |
| 2000-06-30 | 43.54% | AU$147.68 Million ≈ $104.49 Million |
AU$339.16 Million ≈ $239.98 Million |
+35.94pp |
| 1999-06-30 | 7.60% | AU$18.95 Million ≈ $13.41 Million |
AU$249.27 Million ≈ $176.37 Million |
+0.12pp |
| 1998-06-30 | 7.48% | AU$15.01 Million ≈ $10.62 Million |
AU$200.68 Million ≈ $142.00 Million |
-0.88pp |
| 1997-06-30 | 8.36% | AU$32.21 Million ≈ $22.79 Million |
AU$385.18 Million ≈ $272.54 Million |
-- |
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more